Kidney scoring surveillance: predictive machine learning models for clear cell renal cell carcinoma growth using MRI.

Clear cell renal cell carcinoma Decision tree Von Hippel–Lindau

Journal

Abdominal radiology (New York)
ISSN: 2366-0058
Titre abrégé: Abdom Radiol (NY)
Pays: United States
ID NLM: 101674571

Informations de publication

Date de publication:
Apr 2024
Historique:
received: 18 10 2023
accepted: 14 12 2023
revised: 11 12 2023
pubmed: 13 2 2024
medline: 13 2 2024
entrez: 12 2 2024
Statut: ppublish

Résumé

Classification of clear cell renal cell carcinoma (ccRCC) growth rates in patients with Von Hippel-Lindau (VHL) syndrome has several ramifications for tumor monitoring and surgical planning. Using two separate machine-learning algorithms, we sought to produce models to predict ccRCC growth rate classes based on qualitative MRI-derived characteristics. We used a prospectively maintained database of patients with VHL who underwent surgical resection for ccRCC between January 2015 and June 2022. We employed a threshold growth rate of 0.5 cm per year to categorize ccRCC tumors into two distinct groups-'slow-growing' and 'fast-growing'. Utilizing a questionnaire of qualitative imaging features, two radiologists assessed each lesion on different MRI sequences. Two machine-learning models, a stacked ensemble technique and a decision tree algorithm, were used to predict the tumor growth rate classes. Positive predictive value (PPV), sensitivity, and F1-score were used to evaluate the performance of the models. This study comprises 55 patients with VHL with 128 ccRCC tumors. Patients' median age was 48 years, and 28 patients were males. Each patient had an average of two tumors, with a median size of 2.1 cm and a median growth rate of 0.35 cm/year. The overall performance of the stacked and DT model had 0.77 ± 0.05 and 0.71 ± 0.06 accuracies, respectively. The best stacked model achieved a PPV of 0.92, a sensitivity of 0.91, and an F1-score of 0.90. This study provides valuable insight into the potential of machine-learning analysis for the determination of renal tumor growth rate in patients with VHL. This finding could be utilized as an assistive tool for the individualized screening and follow-up of this population.

Identifiants

pubmed: 38347265
doi: 10.1007/s00261-023-04162-y
pii: 10.1007/s00261-023-04162-y
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1202-1209

Informations de copyright

© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.

Références

Bausch B, Jilg C, Gläsker S, Vortmeyer A, Lützen N, Anton A, et al. Renal cancer in von Hippel–Lindau disease and related syndromes. Nature Reviews Nephrology. 2013;9(9):529-38.
doi: 10.1038/nrneph.2013.144 pubmed: 23897319
Varshney N, Kebede AA, Owusu-Dapaah H, Lather J, Kaushik M, Bhullar JS. A review of Von Hippel-Lindau syndrome. Journal of Kidney Cancer and VHL. 2017;4(3):20.
doi: 10.15586/jkcvhl.2017.88 pubmed: 28785532 pmcid: 5541202
Rasmussen RG, Xi Y, Sibley III RC, Lee CJ, Cadeddu JA, Pedrosa I. Association of clear cell likelihood score on MRI and growth kinetics of small solid renal masses on active surveillance. AJR American journal of roentgenology. 2022;218(1):101.
doi: 10.2214/AJR.21.25979 pubmed: 34286596
Whelan EA, Mason RJ, Himmelman JG, Matheson K, Rendon RA. Extended duration of active surveillance of small renal masses: a prospective cohort study. The Journal of Urology. 2019;202(1):57-61.
doi: 10.1097/JU.0000000000000075 pubmed: 30932757
Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, et al. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(1):71–90.
Kim E, Zschiedrich S. Renal cell carcinoma in von hippel–lindau disease—from tumor genetics to novel therapeutic strategies. Frontiers in pediatrics. 2018;6:16.
doi: 10.3389/fped.2018.00016 pubmed: 29479523 pmcid: 5811471
Maher ER, Neumann HP, Richard S. von Hippel–Lindau disease: A clinical and scientific review. European Journal of Human Genetics. 2011;19(6):617-23.
doi: 10.1038/ejhg.2010.175 pubmed: 21386872 pmcid: 3110036
Jilg C, Neumann H, Gläsker S, Schäfer O, Ardelt P, Schwardt M, et al. Growth kinetics in von Hippel-Lindau-associated renal cell carcinoma. Urologia internationalis. 2012;88(1):71-8.
doi: 10.1159/000333348 pubmed: 22156657
Schuhmacher P, Kim E, Hahn F, Sekula P, Jilg CA, Leiber C, et al. Growth characteristics and therapeutic decision markers in von Hippel-Lindau disease patients with renal cell carcinoma. Orphanet journal of rare diseases. 2019;14(1):1-8.
doi: 10.1186/s13023-019-1206-2
Lane BR, Babineau D, Kattan MW, Novick AC, Gill IS, Zhou M, et al. A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. The Journal of urology. 2007;178(2):429-34.
doi: 10.1016/j.juro.2007.03.106 pubmed: 17561141
Kutikov A, Smaldone MC, Egleston BL, Manley BJ, Canter DJ, Simhan J, et al. Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. Eur Urol. 2011;60(2):241-8.
doi: 10.1016/j.eururo.2011.03.029 pubmed: 21458155 pmcid: 3124570
Gopal N, Anari PY, Chaurasia A, Antony M, Wakim P, Linehan WM, Ball M, Turkbey E, Malayeri A. The kidney imaging surveillance scoring system (KISSS): using qualitative MRI features to predict growth rate of renal tumors in patients with von-Hippel Lindau (VHL) syndrome. Abdom Radiol. 2024;49(2):542-50.
doi: 10.1007/s00261-023-04087-6
Xu Q-S, Liang Y-Z. Monte Carlo cross validation. Chemometrics and Intelligent Laboratory Systems. 2001;56(1):1-11.
doi: 10.1016/S0169-7439(00)00122-2
Foster K, Prowse A, van den Berg A, Fleming S, Hulsbeek MM, Crossey PA, et al. Somatic mutations of the von Hippel—Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Human molecular genetics. 1994;3(12):2169-73.
doi: 10.1093/hmg/3.12.2169 pubmed: 7881415
Thrash-Bingham CA, Tartof KD. aHIF: a natural antisense transcript overexpressed in human renal cancer and during hypoxia. Journal of the National Cancer Institute. 1999;91(2):143-51.
doi: 10.1093/jnci/91.2.143 pubmed: 9923855
Chauveau D, Duvic C, Chrétien Y, Paraf F, Droz D, Melki P, et al. Renal involvement in von Hippel-Lindau disease. Kidney international. 1996;50(3):944-51.
doi: 10.1038/ki.1996.395 pubmed: 8872970
Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, et al. von Hippel-Lindau disease. The Lancet. 2003;361(9374):2059-67.
doi: 10.1016/S0140-6736(03)13643-4
Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, et al. Belzutifan for renal cell carcinoma in von Hippel–Lindau disease. New England Journal of Medicine. 2021;385(22):2036-46.
doi: 10.1056/NEJMoa2103425 pubmed: 34818478
WALTHER MM, CHOYKE PL, GLENN G, LYNE JC, RAYFORD W, VENZON D, et al. Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. The Journal of urology. 1999;161(5):1475-9.
doi: 10.1016/S0022-5347(05)68930-6 pubmed: 10210376
McIntosh AG, Ristau BT, Ruth K, Jennings R, Ross E, Smaldone MC, et al. Active Surveillance for Localized Renal Masses: Tumor Growth, Delayed Intervention Rates, and >5-yr Clinical Outcomes. Eur Urol. 2018;74(2):157-64.
doi: 10.1016/j.eururo.2018.03.011 pubmed: 29625756
Choi SJ, Kim H-S, Ahn S-J, Park Y, Choi H-Y. Differentiating radiological features of rapid-and slow-growing renal cell carcinoma using multidetector computed tomography. Journal of Computer Assisted Tomography. 2012;36(3):313-8.
doi: 10.1097/RCT.0b013e3182506c26 pubmed: 22592616
Dodelzon K, Mussi TC, Babb JS, Taneja SS, Rosenkrantz AB. Prediction of growth rate of solid renal masses: utility of MR imaging features—preliminary experience. Radiology. 2012;262(3):884-93.
doi: 10.1148/radiol.11111074 pubmed: 22267588
Farhadi F, Nikpanah M, Paschall AK, Shafiei A, Tadayoni A, Ball MW, et al. Clear Cell Renal Cell Carcinoma Growth Correlates with Baseline Diffusion-weighted MRI in Von Hippel–Lindau Disease. Radiology. 2020;295(3):583.
doi: 10.1148/radiol.2020191016 pubmed: 32255415
Matsumoto R, Abe T, Shinohara N, Murai S, Maruyama S, Tsuchiya K, et al. RENAL nephrometry score is a predictive factor for the annual growth rate of renal mass. International Journal of Urology. 2014;21(6):549-52.
doi: 10.1111/iju.12388 pubmed: 24405437
Mehrazin R, Smaldone MC, Egleston B, Tomaszewski JJ, Concodora CW, Ito TK, et al., editors. Is anatomic complexity associated with renal tumor growth kinetics under active surveillance? Urologic Oncology: Seminars and Original Investigations; 2015: Elsevier.
Anari PY, Lay N, Gopal N, Chaurasia A, Samimi S, Harmon S, et al. An MRI-based radiomics model to predict clear cell renal cell carcinoma growth rate classes in patients with von Hippel-Lindau syndrome. Abdominal Radiology. 2022;47(10):3554-62.
doi: 10.1007/s00261-022-03610-5 pubmed: 35869307
Farhadi F, Nikpanah M, Paschall AK, Shafiei A, Tadayoni A, Ball MW, et al. Clear Cell Renal Cell Carcinoma Growth Correlates with Baseline Diffusion-weighted MRI in Von Hippel–Lindau Disease. Radiology. 2020;295(3):583-90.
doi: 10.1148/radiol.2020191016 pubmed: 32255415

Auteurs

Pouria Yazdian Anari (P)

Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892-1109, USA.

Aryan Zahergivar (A)

Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892-1109, USA.

Nikhil Gopal (N)

Urology Oncology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892-1109, USA.

Aditi Chaurasia (A)

Urology Oncology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892-1109, USA.

Nathan Lay (N)

Artificial Intelligence Resource, National Cancer Institute, National Institutes of Health, Bethesda, USA.

Mark W Ball (MW)

Urology Oncology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892-1109, USA.

Baris Turkbey (B)

Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892-1109, USA.

Evrim Turkbey (E)

Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892-1109, USA.

Elizabeth C Jones (EC)

Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892-1109, USA.

W Marston Linehan (WM)

Urology Oncology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892-1109, USA. linehanm@mail.nih.gov.

Ashkan A Malayeri (AA)

Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892-1109, USA. ashkan.malayeri@nih.gov.

Classifications MeSH